Overview

Concert Pharmaceuticals is a clinical stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert applies its proprietary DCE Platform (deuterated chemical entity) to approved drugs and other agents with known human pharmacological activity to create novel medicines with the potential for enhanced efficacy, better tolerability and improved safety. By leveraging the large body of knowledge on known drugs, Concert focuses its efforts on valuable opportunities where deuterium modification may provide important medical benefits.

Media Contact:
Justine Koenigsberg
Senior Director, Corporate Communications and Investor Relations
781.674.5284
IR@concertpharma.com

Concert Materials and Related Stories

• Corporate Fact Sheet
• Management Backgrounder

Media Feature

Healthcare Global June 2011
Concert Pharmaceuticals Changes the Industry with Deuterium

Concert Publications

• May 2010, Drug Discovery & Development, "Chemistry for Drug Development: Deuterium Modification"
• March 2010, Innovations in Pharmaceutical Technology, "The Development of Deuterium-Containing Drugs"

The following is a selection of news stories in which Concert is featured:

• July 2011, Boston Business Journal, "Roger Tung: In it for long haul as CEO of Concert Pharmaceuticals"
• June 2011, Xconomy, "Concert Pharmaceuticals Hits $4 Million Milestone in GSK Alliance"
• March 2011, Drug Discovery News, "In the Army Now"
• December 2010, Mass High Tech, "Federal Grants Boost Several Mass. Diabetes-Focused Companies"
• November 2010, Boston Business Journal, Mass. wins biotech tax credits
  

Archive of news stories

• Watch Concert Interview on BioBusiness TV (February 2009)
  Streaming Video ¦ High Resolution Video
  

Awards and Recognition

 

	Ernst & Young Entrepreneur of the Year New England Finalist: Roger Tung
	Mass High Tech: Roger Tung Awarded 2009 All-Star Award
	OnDc: Named one of the OnDC's 100 Top Private Companies of 2009
	5th Annual Scrip Awards: 2009 Shortlist in the category of Licensing Deal of the Year
	Boston Business Journal: One of the area's largest venture-funded startups, December 2008
	2008 Fierce 15 Biotechnology Company, June 2008

 

[ back to top ]